艾曲泊帕治疗结缔组织病继发免疫性血小板减少症的临床疗效观察  

Clinical efficacy of eltrombopag olamine in the treatment of immune thrombocytopenia secondary to connective tissue diseases

作　　者：朱宗仁 宋闿迪 汤宝林 Zhu Zongren;Song Kaidi;Tang Baolin(Tianchang People′s Hospital,Tianchang 239300,China;The First Affiliated Hospital of University of Science and Technology of China,Anhui Provincial Hospital,Hefei 230001,China)

机构地区：[1]天长市人民医院,安徽天长239300 [2]中国科学技术大学附属第一医院安徽省立医院,安徽合肥230001

出　　处：《实用药物与临床》2022年第12期1094-1098,共5页Practical Pharmacy and Clinical Remedies

摘　　要：目的分析艾曲泊帕治疗结缔组织病继发免疫性血小板减少症的临床疗效。方法选择2018年8月至2020年7月在天长市人民医院治疗的60例结缔组织病继发免疫性血小板减少症患者,通过双色球分组方式将入选的患者平均分为2组(n=30),对照组采取泼尼松治疗,研究组在此基础上增加艾曲泊帕治疗。比较治疗前后两组患者血小板计数、血小板相关抗体(PAIgG、PAIgM、PAIgA)浓度、Th淋巴细胞因子(IL-2、IL-4、IL-5、IFN-γ)水平、CD19^(+)及CD5^(+)CD19^(+)淋巴细胞百分比、治疗总有效率与复发率、不良反应发生率。结果治疗前,两组患者血小板计数值、血小板相关抗体浓度、Th淋巴细胞因子水平、CD19^(+)及CD5^(+)CD19^(+)淋巴细胞百分比差异无统计学意义(P>0.05)。治疗后,两组患者的血小板计数值、IL-4与IL-5水平升高(P<0.05),血小板相关抗体浓度、IL-2及IFN-γ水平、CD19^(+)及CD5^(+)CD19^(+)淋巴细胞百分比降低(P<0.05);研究组血小板计数值IL-4、IL-5水平显著高于对照组(P<0.05),血小板相关抗体浓度、IL-2及IFN-γ水平、CD19^(+)及CD5^(+)CD19^(+)淋巴细胞百分比低于对照组(P<0.05)。研究组临床总有效率高于对照组(P<0.05),不良反应发生率、复发率均低于对照组(P<0.05)。结论艾曲泊帕治疗结缔组织病继发免疫性血小板减少症效果显著,可调节免疫系统平衡及血小板相关抗体浓度,促进血小板增加,降低复发率,减少不良反应。Objective To analyze the clinical efficacy of eltrombopag olamine in the treatment of immune thrombocytopenia secondary to connective tissue disease.Methods Totally 60 patients with immune thrombocytopenia secondary to connective tissue disease who were treated in Tianchang People′s Hospital from August 2018 to July 2020 were chosen,and they were equally divided into two groups(n=30)by two-color ball grouping.Patients in control group were treated with prednisone,and the patients in study group were treated with eltrombopag olamine and prednisone.The platelet count,platelet-associated antibody concentration(PAIgG,PAIgM,PAIgA),Th lymphocyte factor level(IL-2,IL-4,IL-5 and IFN-γ),percentage of CD19^(+)and CD5^(+)CD19^(+)lymphocytes,total effective rate,recurrence rate and incidence of adverse reactions before and after treatment were compared between the two groups.Results There was no significant difference in platelet count,platelet-associated antibody concentration,Th lymphocyte factor level or percentage of CD19^(+)and CD5^(+)CD19^(+)lymphocytes between the two groups before treatment(P>0.05).After treatment,the platelet count and IL-4 and IL-5 levels of both groups were significantly increased(P<0.05),while the platelet antibody concentration,IL-2 and IFN-γlevels,and percentage of CD19^(+)and CD5^(+)CD19^(+)lymphocytes decreased significantly(P<0.05).After treatment,the platelet count,IL-4 and IL-5 levels in study group were higher than those in control group(P<0.05),while the concentration of platelet-related antibody,the levels of IL-2 and IFN-γ,and the percentage of CD19^(+)and CD5^(+)CD19^(+)lymphocytes were lower than those of control group(P<0.05).The total effective rate of study group was higher than that of control group(P<0.05),while the incidence of adverse reactions and recurrence rate were lower than those of control group(P<0.05).Conclusion Eltrombopag olamine has a remarkable effect on immune thrombocytopenia secondary to connective tissue disease.It can regulate the balance of immune syste

关 键 词：艾曲泊帕 结缔组织病 免疫性血小板减少症 血小板计数 血小板相关抗体 不良反应 

分 类 号：R593.2[医药卫生—内科学] R558.2[医药卫生—临床医学]